PPMD welcomes Dr. Padraig Wright from GlaxoSmithKline as our guest for a webinar on February 22, 2012 at 1pm eastern.
GSK2402968 is an antisense oligonucleotide being developed by GlaxoSmithKline as a potential treatment for boys with Duchenne who have mutations/deletions that can be treated with exon 51 “skipping.” This presentation will describe the current clinical development program, with particular focus on the recruiting studies in ambulant boys with DMD: DMD114044 and the recently initiated US long-term study, DMD114876.
Unfortunately GSK will not allow us to record this webinar, so we will not be able to provide you with a link to replay the presentation afterwards. Please make sure to join us LIVE at 1pm eastern so you don't miss out!
Read more PPMD Blogs